Lung and liver transplantation in patients with alpha-1 antitrypsin deficiency

Martin R. Zamora and Ali Ataya

Abstract: Alpha-1 antitrypsin (AAT) augmentation is effective in slowing the progression of emphysema due to AAT deficiency (AATD) but cannot prevent eventual progression to end-stage lung disease and complete respiratory failure, which is the leading cause of death for individuals with severe AATD. When patients develop end-stage lung disease, lung transplantation is the only treatment option available, and this can improve lung physiology and patient health status. The available data suggest that survival rates for lung transplantation are significantly higher for patients with AATD-related chronic obstructive pulmonary disease (COPD) compared with non-AATD-related COPD, but, conversely, there is a higher risk of common post-lung transplant complications in patients with AATD versus non-AATD COPD. Nevertheless, lung transplantation (single and bilateral) is favorable for patients with AATD. After respiratory failure, the second leading cause of death in patients with AATD is liver disease, for example, cirrhosis and hepatocellular carcinoma, caused by the accumulation of mutant forms of AAT retained within the liver. As with lung disease, the only treatment option for end-stage liver disease is liver transplantation. Survival rates for patients with AATD undergoing liver transplantation are also favorable, and patients, particularly pediatric patients, have benefitted from advancements in peri-/post-surgical care. As the majority of AAT is produced by the liver, the AAT phenotype of the recipient becomes that of the donor, meaning that AAT serum levels should be normalized (if the donor is AAT-replete), halting further lung and liver disease progression. However, post-liver transplant respiratory function may continue to decline in line with normal age-related lung function decline. In the most severe cases, where patients have simultaneous end-stage lung and liver disease, combined lung and liver transplantation is a treatment option with favorable outcomes. However, there is very little information available on this procedure in patients with AATD.

Keywords: alpha-1 antitrypsin, alpha-1 antitrypsin deficiency, combined lung and liver transplant, liver transplant, lung transplant, post-transplant survival

Received: 13 January 2021; revised manuscript accepted: 24 February 2021.
worldwide, following non-AATD chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis, and cystic fibrosis. Compared with patients undergoing lung transplantation due to non-AATD COPD, patients undergoing lung transplantation due to AATD are, on average, 10 years younger and have had less exposure to tobacco smoke, making them more suitable for lung transplantation. However, there is conflicting data on post-lung transplant survival in AATD compared with other transplant indications. Similarly, for AATD patients with end-stage liver disease, which may be necessary in children as well as adults, the only effective treatment is liver transplantation.

The transplant-related healthcare burden associated with AATD appears to be disproportionate compared with its status as a rare disease, and transplantation is a rarely discussed area of AATD care, as guidelines focus more on the treatment and monitoring of patients up to lung transplantation. However, it is important to be aware of outcomes in AATD post-lung and liver transplantation so that patients can be provided with all the necessary information before deciding whether or not to go ahead with these treatment options. This chapter of the AATD review series discusses both types of transplantation and the associated outcomes in patients with AATD, as well as combined lung and liver transplantation, which may be the only treatment option for patients with end-stage emphysema complicated by cirrhosis, or for those with cirrhosis and advanced emphysema who would not be expected to survive lung or liver transplantation alone.

Lung transplantation
As a result of the efforts of transplant centers worldwide, there is now substantial information available regarding the incidence – and associated outcomes – of lung transplantation related to AATD. Despite being a rare disease, AATD accounts for a substantial proportion of all lung transplantation cases. Between 1995 and 2015, the primary indication for 50,002 adult lung transplantations in the United States (US) was COPD (n = 18,241; 36.5%), and 2568 of these cases (5.1%) were as a result of AATD-related COPD. In Sweden between 1987 and 2015, out of 14,644 patients who required long-term oxygen therapy due to COPD, a higher proportion of patients with AATD-related COPD underwent lung transplantation (19%) than patients with non-AATD-related COPD (1%). This is likely due to AATD patients having more impaired diffusion capacity than non-AATD COPD patients, possibly as a result of a more emphysema-predominant phenotype compared with non-AATD COPD patients. This may account for the high representation of AATD patients within lung transplant statistics.

In the UK, a study from the Antitrypsin Deficiency Assessment and Programme for Treatment (ADAPT) registry between 1996 and 2011 reported favorable post-lung transplant survival rates in patients with AATD of 81.3%, 74.2%, 52.9%, and 45.2% at 90 days, 1 year, 5 years, and 10 years, respectively. Notably, these rates were no better than those of matched control patients who did not undergo lung transplantation. However, patients that did undergo lung transplantation showed significant improvement in forced expiratory volume in 1 s (FEV₁) and all domains of the St. George’s Respiratory Questionnaire (both p < 0.002), demonstrating beneficial effects of transplantation outside of survival.

Outcomes in AATD versus non-AATD COPD
There are several studies reporting that outcomes of lung transplantation in patients with AATD differ from those with non-AATD COPD (Table 1). Studies by Tanash et al. and Fakhro et al. report superior short- and long-term survival in patients with AATD undergoing lung transplantation compared with those with non-AATD COPD, whereas Spratt et al., Gulack et al., and Riley and Lascano report worse short-term survival but better long-term survival (Table 1; Figure 1). There are also differences in survival reported between single lung versus bilateral lung transplantation within these two patient cohorts, with higher survival reported for bilateral lung transplantation irrespective of whether the transplantation was due to AATD or non-AATD COPD (Table 1). Nevertheless, reducing the incidence of post-transplant infection remains a major challenge to lung transplant survival for any etiology. When compared with non-AATD COPD, lung transplant patients with AATD are reported to have increased post-transplant mortality due to infection and liver disease.
Table 1. Reported outcomes of lung transplantation in patients with AATD and non-AATD COPD.

| Outcomes following lung transplantation | AATD       | Non-AATD COPD | Statistical significance | Reference                |
|----------------------------------------|------------|---------------|--------------------------|--------------------------|
| Number of patients                     | 128        | 214           | Not given                | Tanash et al.\(^{14}\) Study: 1990–2012 |
| Mean [range] age                       | 53 [32–67] years | 57 [32–70] years | \(p = 0.000\)            |                          |
| Median survival time                   | 12 years   | 6 years       | \(p = 0.000\)            |                          |
| Survival rate:                         |            |               |                          |                          |
| 5 years [%]                            | 75         | 60            | \(p = 0.002\)            |                          |
| 10 years [%]                           | 59         | 31            | \(p = 0.000\)            |                          |
| Number of patients                     | 42         | 52            | Not given                | Fakhro et al.\(^{15}\) Study: 1990–2014 |
| Mean [range] age                       | 51 [12–71] years |               |                          |                          |
| Survival rate:                         |            |               | \(p > 0.05\) (all timepoints) |                          |
| 1 year [%]                             | 93 [CI 86–99] | 83 [CI 75–93] |                          |                          |
| 3 years [%]                            | 81 [CI 71–92] | 70 [CI 60–82] |                          |                          |
| 5 years [%]                            | 70 [CI 58–84] | 59 [CI 48–73] |                          |                          |
| 10 years [%]                           | 56 [CI 42–73] | 29 [CI 18–47] |                          |                          |
| 15 years [%]                           | 32 [CI 19–55] | 22 [CI 12–41] |                          |                          |
| Total number of deaths >12 months      | 26         | 29            | Not given                |                          |
| Cause of death:                        |            |               |                          |                          |
| Organ rejection [%]                    | 6 [23]     | 7 [24]        |                          |                          |
| Infection [%]                          | 7 [27]     | 8 [28]        |                          |                          |
| Malignancy [%]                         | 4 [15]     | 5 [17]        |                          |                          |
| Other causes [%]                       | 9 [35]     | 9 [31]        |                          |                          |
| Number of patients                     | 98         | 287           | Not given                | Spratt et al.\(^{16}\) Study: 1988–2015 |
| Mean [±SD] age                         | 51.7 ± 8.0 | 58.1 ± 6.1    | \(p < 0.001\)            |                          |
| Survival rate:                         |            |               | \(p = 0.001\) (all timepoints) |                          |
| 90 days [%]                            | 91 [85–96] | 95 [92–97]    |                          |                          |
| 1 year [%]                             | 84 [77–92] | 87 [83–91]    |                          |                          |
| 3 years [%]                            | 75 [67–84] | 74 [69–79]    |                          |                          |
| 5 years [%]                            | 67 [57–77] | 56 [50–62]    |                          |                          |
| 10 years [%]                           | 46 [35–56] | 23 [17–29]    |                          |                          |

(Continued)
### Table 1. (Continued)

| Outcomes following lung transplantation | AATD | Non-AATD COPD | Statistical significance | Reference |
|----------------------------------------|------|---------------|--------------------------|-----------|
| Incidence of all GI complications:     |      |               |                          |           |
| 90 days (%)                            | 4.88 | 6.08          |                          |           |
| 1 year (%)                             | 10.37| 9.01          |                          |           |
| 5 years (%)                            | 16.78| 11.90         |                          |           |
| Incidence of GI bleed:                 |      |               |                          |           |
| 90 days (%)                            | 2.44 | 2.70          |                          |           |
| 1 year (%)                             | 2.44 | 2.70          |                          |           |
| 5 years (%)                            | 5.48 | 4.50          |                          |           |
| Incidence of diverticulitis:           |      |               |                          |           |
| 90 days (%)                            | 2.38 | 0             |                          |           |
| 1 year (%)                             | 2.38 | 0             |                          |           |
| 5 years (%)                            | 2.38 | 1.07          |                          |           |
| Incidence of HPB complications:        |      |               |                          |           |
| 90 days (%)                            | 2.44 | 4.05          |                          |           |
| 1 year (%)                             | 10.37| 6.98          |                          |           |
| 5 years (%)                            | 13.70| 9.04          |                          |           |
| Number of patients:                    |      |               |                          | Gulack *et al.*<sup>17</sup> Study: 1990–2013 |
| Overall                                | 1394 | 8175          |                          |           |
| Single lung Tx                         | 679  | 5009          |                          |           |
| Bilateral lung Tx                      | 715  | 3166          |                          |           |
| Median (IQR) age:                      |      |               |                          |           |
| Single lung Tx                         | 51 (45–56) years | 59 (54–62) years | *p* < 0.001     |           |
| Bilateral lung Tx                      | 50 (45–56) years | 58 (53–62) years | *p* < 0.001     |           |
| Survival rate (single lung Tx; pre-LAS):|      |               |                          |           |
| 1 year (%)                             | 74.7 | 83.1          | *p* < 0.001              |           |
| 5 years (%)                            | 45.7 | 48.3          | *p* = 0.218              |           |
| 10 years (%)                           | 24.0 | 20.1          | *p* = 0.046              |           |
| Survival rate (single lung Tx; post-LAS):|      |               |                          |           |
| 1 year (%)                             | 84.2 | 86.9          | *p* = 0.606              |           |
| 5 years (%)                            | 51.1 | 51.7          | *p* = 0.947              |           |
Table 1. (Continued)

| Outcomes following lung transplantation | AATD   | Non-AATD COPD | Statistical significance | Reference                      |
|----------------------------------------|--------|---------------|--------------------------|--------------------------------|
| Survival rate (bilateral lung Tx; pre-LAS): |        |               |                          |                                |
| 1 year (%)                            | 83.6   | 85.5          | \( p = 0.220 \)          |                                |
| 5 years (%)                           | 61.8   | 56.4          | \( p = 0.016 \)          |                                |
| Survival rate (bilateral lung Tx; post-LAS): |        |               |                          |                                |
| 1 year (%)                            | 88.7   | 86.5%         | \( p = 0.327 \)          |                                |
| 5 years (%)                           | 62.7   | 56.9          | \( p = 0.218 \)          |                                |
| Number of patients                    | 1156   | Not stated    | Not given                | Riley and Lascano\(^{18}\) Study: 1992–2019 |
| Median age                            | 51.9 years | 59.7 years   | Not given                |                                |
| Median (IQR) survival time:           |        |               |                          |                                |
| Overall                               | 6.4 [1.8–12.2] years | 5.5 [2.2–10.3] years | Not given                |                                |
| Single lung Tx                        | 4.4 [1.0–10.1] years | 4.9 [1.8–9.1] years | Not given                |                                |
| Bilateral lung Tx                     | 7.7 [2.3–14.2] years | 6.6 [2.6–12.1] years | Not given                |                                |
| Overall survival rate:                |        |               |                          |                                |
| 1 year (%)                            | 82     | 86            |                          |                                |
| 5 years (%)                           | 56     | 54            |                          |                                |
| 10 years (%)                          | 34     | 26            |                          |                                |
| Survival rate (single lung Tx):       |        |               |                          |                                |
| 1 year (%)                            | 75     | 84            |                          |                                |
| 5 years (%)                           | 47     | 49            |                          |                                |
| 10 years (%)                          | 25     | 21            |                          |                                |
| Survival rate (bilateral lung Tx):    |        |               |                          |                                |
| 1 year (%)                            | 86     | 88            |                          |                                |
| 5 years (%)                           | 62     | 59            |                          |                                |
| 10 years (%)                          | 40     | 34            |                          |                                |
| Total number of deaths                | 1027   | 6817          | Not given                |                                |
| Deaths due to infection (%)           | 235 [23] | 1340 [20]    | \( p = 0.02 \)          |                                |

AAT, alpha-1 antitrypsin; AATD, AAT deficiency; COPD, chronic obstructive pulmonary disease; GI, gastrointestinal; HPB, hepatopancreatobiliary; IQR, interquartile range; LAS, lung allocation score; SD, standard deviation; Tx, transplant.

More recently, however, the above differences in post-transplant survival between patients with AATD versus non-AATD COPD have not been observed in the US, which likely results from implementation of the lung allocation score (LAS) in 2005.\(^{17}\) The LAS was devised to
Figure 1. Survival following lung transplantation is decreased in the short-term but increased in the long-term in patients with AATD versus non-AATD-related COPD. Reproduced with permission from Spratt et al. AAT, alpha-1 antitrypsin; AATD, AAT deficiency; COPD, chronic obstructive pulmonary disease.

There are, therefore, conflicting reports on the overall value of lung transplantation in AATD, with early studies suggesting longer survival in patients with AATD, but with worse short-term survival. These differences are less apparent in recent studies in the US, which may be attributed to the more widespread use of AAT augmentation and the LAS. Further studies could investigate whether patients with AATD today have significantly worse clinical state than those with non-AATD COPD at the time of lung transplantation.

Outside of survival, the decline in FEV₁ pre-lung transplantation is highly variable for patients with AATD and non-AATD COPD, and, following single lung transplantation, the rate of decline in FEV₁% predicted appears to be no different between AATD and non-AATD COPD patients. However, a faster rate of decline in FEV₁% predicted has been observed in AATD patients undergoing a double lung transplantation. Prior to lung transplantation, other surgical intervention approaches, such as endobronchial lung volume reduction (ELVR) and endobronchial coil treatment, may be suitable treatment options for patients with AATD-associated lung disease, and are discussed in more detail in the chapter by Barjaktarevic and Campos.

Impact of AAT augmentation

Treatment of AATD with intravenous infusion of exogenous AAT protein (AAT augmentation) aims to slow the progression of lung destruction and has demonstrated significant slowing of emphysema progression related to AATD, prolonging the time to terminal respiratory failure. Registry data also suggests that AAT augmentation confers a survival advantage compared with no treatment, which is supported by an extrapolation analysis of the lung densitometry data from the RAPID clinical trial program. AAT augmentation plays an important role in postponing lung transplantation, but its role following lung transplantation is unclear and needs to be explored. Indeed, most reports of transplantation outcomes in the previous section do not provide information on the use of AAT augmentation post-lung transplantation in patients with AATD. In the US study that compared outcomes of AATD-related COPD and non-AATD-related COPD lung transplant recipients, only three double lung transplant patients with AATD
(n = 45) received AAT augmentation within 3 years following transplantation, and the effects of AAT augmentation on post-transplant survival were not investigated. However, AAT augmentation use post-lung transplantation was reported to help reverse what seemed to be impeding chronic rejection in one patient.

In the post-lung transplant period, there is excessive inflammation and neutrophil activity (with an increase in neutrophil elastase) in patients with AATD, which can further increase during periods of infection and/or transplant rejection. Therefore, treatment with AAT, which has been shown to assist in the resolution of chronic inflammation in the lung endothelium, may be beneficial to AATD patients following lung transplantation. In line with this, there has been interest in the utility of AAT augmentation for transplant indications including graft-versus-host disease and lung transplantation in general, with several pre-clinical and early-phase studies conducted in this area. Pre-clinical animal models have also shown a potential benefit of AAT augmentation in terms of reducing allograft injury, but this needs to be confirmed in human trials. Regarding AAT augmentation utilization pre-transplantation, one study in Germany has reported differences in post-transplant survival in patients who had previously received AAT between 1999 and 2012, compared with those who had not received the therapy. At 1 year post-transplant, there was a trend towards lower survival in patients who received AAT augmentation prior to transplantation. This difference became statistically significant in the long-term (between 3 and 10 years post transplantation; \( p \approx 0.01 \)). The results were unexpected and the authors had no definitive explanation, although it was postulated that patients who had previously received AAT augmentation may have had more severe disease prior to transplantation, which could have impacted the post-transplant outcome. Alternatively, given that AAT augmentation is considered to be an immunomodulatory therapy, sudden therapy discontinuation could have an adverse effect on post-lung transplant survival, which could suggest that a tapering approach is indicated in the period immediately after transplantation. However, more research is required in this area.

Although resolution of emphysema as a result of lung transplantation necessitates discontinuation of AAT augmentation, the underlying genetic deficiency remains unresolved. Indeed, the recurrence of emphysema in patients with AATD has been documented twice in the literature; in a patient 11 years post lung transplantation, and in another 2 years post lung transplantation. In both cases, patients had recommenced smoking. In these cases, the reintroduction of AAT augmentation is justified if patients abstain from smoking. In contrast, AAT augmentation is not recommended following liver transplantation related to AATD, as transplantation of a donor liver from an AAT-replete individual will result in the normal production and secretion of endogenous AAT.

Liver transplantation

The background to the pathophysiology and progression of liver disease in AATD is covered in an earlier chapter of this series of reviews. However, as previously mentioned, although supportive care and symptomatic treatment is warranted for patients with AATD, liver transplantation is the only available curative treatment for end-stage liver disease related to AATD. In adults, liver disease is often undetected until cirrhosis or hepatocellular carcinoma is evident, which are treatable through liver transplantation. In children with AATD, some may experience jaundice and have no further complications, whilst some may develop liver cirrhosis and require liver transplantation. Therefore, the American Thoracic Society/European Respiratory Society recommend liver assessment through liver function testing in all individuals most at risk of AATD-associated liver disease (patients with the \( \text{PI}^{*} \text{ZZ} \) genotype). However, additional testing may be necessary as testing serum liver enzymes alone may not be sufficient; in a study of 403 patients with AATD (\( \text{PI}^{*} \text{ZZ} \)), liver enzymes were increased in only a minority of patients [19.1% for alanine aminotransferase, 12.7% for aspartate aminotransferase (AST), 23.7% for \( \gamma \)-glutamyl transferase and 8.6% for alkaline phosphatase]. Non-invasive liver assessments, as for other causes of chronic liver disease, such as the liver stiffness measurement and the AST to platelet ratio index, may be useful to identify those at risk of AATD-associated liver disease.

In AATD, disease progression to end-stage liver disease requiring liver transplantation occurs
Therapeutic Advances in Chronic Disease 12

more commonly in males, with 73% of those requiring liver transplantation being male, despite rates of liver disease diagnosis being similar between men and women. Increased body mass index has also been found to be a risk factor for end-stage liver disease requiring liver transplantation in AATD. The course of pulmonary disease after liver transplantation in both adults and children is poorly understood, but, recently, pulmonary hypertension and pulmonary embolism were reported more frequently in adult patients with AATD compared with those undergoing liver transplantation without AATD. However, further studies are required to clarify the impact of liver transplantation on pulmonary function. Nevertheless, liver transplantation is associated with favorable survival rates in both adults and children with AATD.

Outcomes
Liver transplantation is associated with favorable survival rates for a variety of diagnoses, including AATD. In one large study of survival rates from 5180 liver transplantations (116 of which were related to AATD) in 37 different centers in the US between 1982 and 1991, the 5-year survival rate for patients undergoing liver transplantation related to AATD was 72.9%. This was slightly higher than the overall average 5-year survival rate of 69.2%, and similar to survival rates for primary (71.0%) and secondary biliary cirrhosis (81.4%), primary sclerosing cholangitis (73.5%), and Wilson’s disease (79.2%), but substantially higher than for hemochromatosis (43.1%), liver cancer (33.6%), and hepatitis B (31.9%). In another US study evaluating liver transplantation over a later period (1995–2004), a higher survival rate at 5 years post-liver transplantation in patients with AATD was reported (83%; Figure 2). The improvements in post-transplant survival in this study may reflect advances in supportive treatments and peri-/post-surgical care over time.

In children with AATD, liver transplantation is also associated with favorable long-term outcomes in terms of survival, growth, and quality of life. A study using the United Network for Organ Sharing (UNOS) database reported a 5-year survival rate of 90% in pediatric liver transplant recipients with AATD, somewhat higher than the rate of 83% reported among adult liver transplant recipients with AATD. A study from another US center analyzing survival following liver transplantation in pediatric patients with AATD highlighted the importance of novel treatments in determining post-transplant outcomes. The 5-year survival rate increased from 33% in the period of 1969–1984 to 77% following the introduction of cyclosporine in 1985, and 100% following the introduction of tacrolimus in 1995. More recently, in a study of 32 adults and 58 children with the AATD undergoing liver transplantation between 1982 and 2017 in Europe, overall patient survival rates were 97.8%, 95.5%, 95.5, 92.0% and 89.1% at 1, 5, 10, 15, and 20 years, respectively.

The AATD genotype may have a minor influence on survival rates post liver transplantation, with one study, predominantly in adults, reporting respective 3-, 5-, and 10-year survival rates of 83%, 80%, and 72% for PI*ZZ patients, compared with 86%, 79%, and 79% for PI*SZ patients. Despite these minor differences, the survival rate following liver transplantation for both adult and pediatric patients with severe AATD is considered excellent.

Normalization of AAT production
A specific benefit of liver transplantation is that it should normalize the secretion of AAT, potentially reducing further disease-related decline in lung function and liver disease. This premise is
Supported by studies where liver transplantation was associated with a rise in serum AAT levels\textsuperscript{53,54} as well as findings from a small US study conducted between 1999 and 2003, which collected lung function data from seven patients with AATD from before and after liver transplantation.\textsuperscript{55} Despite an expected decline in FEV\textsubscript{1} of 250 ml during the 3-year period post-liver transplant, there was no significant change in lung function in these liver transplant recipients.\textsuperscript{55} The authors concluded that liver transplantation likely prevented progression of pulmonary disease in these patients.\textsuperscript{55} However, another US study has reported variable results.\textsuperscript{53} In a small group of PI*ZZ patients following liver transplantation, the majority of patients (\(n=11\)) experienced a decline in FEV\textsubscript{1} whereas others (\(n=6\)) showed an improvement in FEV\textsubscript{1}.\textsuperscript{53} These data suggest that further studies are required to fully understand the impact of liver transplantation on lung function. It is important to note that, although liver transplantation normalizes AAT levels and there have been some reports of lung function improvement, lung function may continue to decline at a rate comparable with that of normal age-related decline in lung function following liver transplantation.\textsuperscript{56}

Complete normalization of AAT production following liver transplantation will occur only if the donor liver is from an AAT-replete (PI*MM) individual. However, as not every center routinely tests donors for AATD, it is possible for a liver transplant recipient to receive a liver with a severe AATD genotype. Indeed, cases of PI*MZ, PI*ZZ, and PI*SZ liver transplantation have been reported.\textsuperscript{45,57} The recipient of an affected liver may initially go unnoticed, as testing AAT levels post-liver transplantation is not performed routinely.\textsuperscript{45} Testing should therefore be considered for unexplained liver function test abnormalities post-liver transplantation, or if periodic acid-Schiff and D-globules are found on donor organ biopsies.\textsuperscript{45} Alternatively, non-invasive genetic testing should be performed, which would identify patients with borderline serum AAT levels.

**Combined lung and liver transplant**

Combined lung and liver transplant is a viable treatment option for patients with both end-stage lung and liver disease who would otherwise not survive with either transplantation alone.\textsuperscript{10} This type of combined transplant is not commonly performed due to the complexity of the procedure, and so there are currently no recipient selection criteria reported in the literature. There is also no listing criteria for patients with AATD-related lung and liver disease, and there is limited information regarding patient characteristics and outcomes, particularly in patients with AATD. In one study of eight patients undergoing combined lung and liver transplantation between 2009 and 2012 in one US center, overall survival at 1 year was 71.4\%, but only one combined transplant was related to AATD.\textsuperscript{10} In a German study with 13 patients undergoing combined lung and liver transplant between 1999 and 2003, two combined transplants were related to AATD and overall survival rates at 1, 3, and 5 years were 69\%, 62\%, and 49\%, respectively, for the seven patients that did not succumb to post-operative complications.\textsuperscript{59} Although combined transplant is more commonly performed in patients with cystic fibrosis, the limited data available suggest that it can be performed successfully with favorable outcomes in carefully selected patients with AATD. Infectious complications are the most common cause of death related to this procedure, but improvements in surgical technique, treatment in the intensive care unit, and medical and immunosuppressive therapy have helped to make combined lung and liver transplantation a viable procedure when performed at experienced centers.\textsuperscript{59}

**Conclusions**

Lung and liver transplantation are viable treatment options for end-stage lung and liver disease in patients with AATD, and data shows that post-lung and liver transplant survival is favorable. Patients show improved lung function and quality of life post lung transplantation, and although some differences have been reported in the past, recent data in the age of the LAS and AAT augmentation suggest that outcomes of lung transplantation in patients with AATD are similar to those with non-AATD-related COPD. The effect of prior AAT augmentation on survival following lung transplant requires further investigation.

Liver transplantation in patients with AATD is associated with favorable long-term survival rates and is the only available intervention for addressing severe liver disease related to AATD. Survival rates are very good for both adult and pediatric
transplant recipients and has increased over the past decades as better supportive treatments and care have become available. A specific benefit of liver transplantation in patients with AATD is that physiological AAT levels are restored with the introduction of a liver expressing wild-type AAT, which should theoretically slow the progression of AATD-related lung disease, and preclude the reoccurrence of AATD-related liver disease. In the most severe cases of AATD, where patients have end-stage lung and liver disease simultaneously, a combined lung and liver transplant may be a feasible treatment option, but more data on this procedure is required for patients with AATD.

Acknowledgements
Medical writing assistance was provided by Ben McDermott and Steven Foster of Meridian HealthComms Ltd., Plumley, UK, in accordance with good publication practice (GPP3), funded by CSL Behring.

Author contributions
Both authors contributed to the writing of the manuscript, reviewed the manuscript, and approved the manuscript for submission.

Conflict of interest statement
The authors declare that there is no conflict of interest.

References
1. American Thoracic Society and European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. *Am J Respir Crit Care Med* 2003; 168: 818–900.
2. Stoller JK and Tejwani V. The spectrum of clinical sequelae associated with alpha-1 antitrypsin deficiency. *Ther Adv Chronic Dis* 2021; 12(2S): 3–11.
3. Stoller JK, Tomaszewski J Jr, Crystal RG, et al. Mortality in individuals with severe deficiency of alpha-1-antitrypsin: findings from the national heart, lung, and blood institute registry. *Chest* 2005; 127: 1196–1204.
4. Patel D and Teckman J. Liver disease with unknown etiology: have you ruled out alpha-1 antitrypsin deficiency? *Ther Adv Chronic Dis* 2021; 12(2S): 25–32.
5. Barjaktarevic I and Campos M. Management of lung disease in alpha-1 antitrypsin deficiency: what we do and what we don’t know. *Ther Adv Chronic Dis* 2021; 12(2S): 49–63.
6. Chapman KR, Burdon JGW, Pitulainen E, et al. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. *Lancet* 2015; 386: 360–368.
7. McElvaney NG, Burdon J, Holmes M, et al. Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE). *Lancet Respir Med* 2017; 5: 51–60.
8. Chambers DC, Yusen RD, Cherikh WS, et al. The registry of the international society for heart and lung transplantation: thirty-fourth adult lung and heart-lung transplantation report-2017; focus theme: allograft ischemic time. *J Heart Lung Transplant* 2017; 36: 1047–1059.
9. Giacoboni D, Barrechegeuren M, Esquinas C, et al. Characteristics of candidates for lung transplantation due to chronic obstructive pulmonary disease and alpha-1 antitrypsin deficiency emphysema. *Arch Bronconeumol* 2015; 51: 379–383.
10. Yi SG, Burroughs SG, Loebe M, et al. Combined lung and liver transplantation: analysis of a single-center experience. *Liver Transpl* 2014; 20: 46–53.
11. Yusen RD, Edwards LB, Dipchand AI, et al. The registry of the international society for heart and lung transplantation: thirty-third adult lung and heart-lung transplant report-2016; focus theme: primary diagnostic indications for transplant. *J Heart Lung Transplant* 2016; 35: 1170–1184.
12. Ekstrom M and Tanash H. Lung transplantation and survival outcomes in patients with oxygen-dependent COPD with regard to their alpha-1 antitrypsin deficiency status. *Int J Chron Obstruct Pulmon Dis* 2017; 12: 3281–3287.
13. Stone HM, Edgar RG, Thompson RD, et al. Lung transplantation in alpha-1-antitrypsin deficiency. *COPD* 2016; 13: 146–152.
14. Tanash HA, Riise GC, Ekstrom MP, et al. Survival benefit of lung transplantation for chronic obstructive pulmonary disease in Sweden. *Ann Thorac Surg* 2014; 98: 1930–1935.
15. Fakhro M, Ingemansson R, Skog I, et al. 25-year follow-up after lung transplantation at Lund University Hospital in Sweden: superior results.
obtained for patients with cystic fibrosis. *Interact Cardiovasc Thorac Surg* 2016; 23: 65–73.

16. Spratt JR, Brown RZ, Rudser K, et al. Greater survival despite increased complication rates following lung transplant for alpha-1-antitrypsin deficiency compared to chronic obstructive pulmonary disease. *J Thorac Dis* 2019; 11: 1130–1144.

17. Gulack BC, Mulvihill MS, Ganapathi AM, et al. Survival after lung transplantation in recipients with alpha-1 antitrypsin deficiency compared to other forms of chronic obstructive pulmonary disease: a national cohort study. *Transpl Int* 2018; 31: 45–55.

18. Riley L and Lascano J. Clinical outcomes and survival following lung transplantation in patients with alpha-1 antitrypsin deficiency. *Respir Med* 2020; 172: 106145.

19. Bhatt SP, Soler X, Wang X, et al. Association between functional small airway disease and FEV1 decline in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2016; 194: 178–184.

20. Hiller A-M, Piitulainen E, Jehpsson L, et al. Decline in FEV1 and hospitalized exacerbations in individuals with severe alpha-1 antitrypsin deficiency. *Int J Chron Obstruct Pulmon Dis* 2019; 14: 1075–1083.

21. Banga A, Gildea T, Rajeswaran J, et al. The natural history of lung function after lung transplantation for α1-antitrypsin deficiency. *Am J Respir Crit Care Med* 2014; 190: 274–281.

22. Ellis P, Holm K, Choate R, et al. Comparison of outcomes in augmentation naive and augmented patients with alpha-1 antitrypsin deficiency related lung disease. *Eur Respir J* 2019; 54 (Suppl. 63): PA3383.

23. The Alpha-1 Antitrypsin Deficiency Registry Study Group. Survival and FEV1 decline in individuals with severe deficiency of alpha-1-antitrypsin. *Am J Respir Crit Care Med* 1998; 158: 49–59.

24. Miravitlles M, Dirksen A, Ferrarotti I, et al. European Respiratory Society statement: diagnosis and treatment of pulmonary disease in alpha-1-antitrypsin deficiency. *Eur Respir J* 2017; 50: 1700610.

25. Teschler H. Long-term experience in the treatment of α1 antitrypsin deficiency: 25 years of augmentation therapy. *Eur Respir Rev* 2015; 24: 46–51.

26. Meyer KC, Nunley DR, Dauber JH, et al. Neutrophils, unopposed neutrophil elastase, and alpha1-antiprotease defenses following human lung transplantation. *Am J Respir Crit Care Med* 2001; 164: 97–102.

27. Lockett AD, Kimani S, Ddungu G, et al. α1-Antitrypsin modulates lung endothelial cell inflammatory responses to TNF-α. *Am J Resp Cell Mol Biol* 2013; 49: 143–150.

28. Lewis EC, Mizrahi M, Toledano M, et al. Alpha1-antitrypsin monotherapy induces immune tolerance during islet allograft transplantation in mice. *Proc Natl Acad Sci U S A* 2008; 105: 16236–16241.

29. Tawara I, Sun Y, Lewis EC, et al. Alpha-1-antitrypsin monotherapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation. *Proc Natl Acad Sci U S A* 2012; 109: 564–569.

30. National Institutes of Health. A pilot study of alpha-1-antitrypsin (AAT) in steroid refractory acute graft vs host disease (NCT01700036). ClinicalTrials.gov website, https://clinicaltrials.gov/ct2/show/NCT01700036 (2012, accessed 27 July 2020).

31. National Institutes of Health. Alpha 1 anti-trypsin deficiency. *Respir Med Case Rep* 2020; 31: 101309.

32. Magenau JM, Goldstein SC, Peltier D, et al. α1-Antitrypsin monotherapy reduces graft-versus-host disease in patients with acute graft versus host disease after experimental allogeneic bone marrow transplantation. *Proc Natl Acad Sci U S A* 2012; 109: 564–569.

33. Emtiazjoo AM, Hu H, Lu L, et al. Alpha-1 antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease. *Blood* 2018; 131: 1372–1379.

34. Conrad A, Janciauskiene S, Köhnlein T, et al. Impact of alpha 1-antitrypsin deficiency and prior augmentation therapy on patients’ survival after lung transplantation. *Eur Respir J* 2017; 50: 1700962.

35. Mal H, Guignabert C, Thabut G, et al. Recurrence of pulmonary emphysema in an α1-proteinase inhibitor-deficient lung transplant recipient. *Am J Respir Crit Care Med* 2004; 170: 811–814.

36. Ataya A. Recurrence of emphysema post-lung transplantation in a patient with alpha 1 antitrypsin deficiency (AATD). *Respir Med Case Rep* 2020; 31: 101309.

37. Sandhaus RA, Turino G, Brantly ML, et al. The diagnosis and management of alpha-1 antitrypsin deficiency. *J Thorac Dis* 2019; 11: 1130–1144.
deficiency in the adult. *Chronic Obstr Pulm Dis* 2016; 3: 668–682.

38. Zamora M. Surgery for patients with alpha 1 antitrypsin deficiency: a review. *Am J Surg* 2019; 218: 639–647.

39. Townsend S, Newsome P and Turner AM. Presentation and prognosis of liver disease in alpha-1 antitrypsin deficiency. *Expert Rev Gastroenterol Hepatol* 2018; 12: 745–747.

40. Hamesch K, Mandorfer M, Pereira VM, et al. Liver fibrosis and metabolic alterations in adults with alpha-1-antitrypsin deficiency caused by the Pi*ZZ mutation. *Gastroenterology* 2019; 157: 705–719.e718.

41. Schneider CV, Hamesch K, Gross A, et al. Liver phenotypes of European adults heterozygous or homozygous for Pi*Z variant of AAT (Pi*MZ vs Pi*ZZ genotype) and noncarriers. *Gastroenterology* 2020; 157: 705–719.e718.

42. Townsend SA, Edgar RG, Ellis PR, et al. Systematic review: the natural history of alpha-1 antitrypsin deficiency, and associated liver disease. *Aliment Pharmacol Ther* 2018; 47: 877–885.

43. Bowls CL, Willner I, Zern MA, et al. Factors associated with advanced liver disease in adults with alpha-1-antitrypsin deficiency. *Clin Gastroenterol Hepatol* 2005; 3: 390–396.

44. Abu Rmilah A, Fencl R, Watt K, et al. Association of α 1 antitrypsin phenotype and development of advanced liver disease and pulmonary complications before and after liver transplantation. *Transplantation*. Epub ahead of print 6 July 2020. DOI: 10.1097/ TP.0000000000003390.

45. Clark VC. Liver transplantation in alpha-1 antitrypsin deficiency. *Clin Liver Dis* 2017; 21: 355–365.

46. Kilpe VE, Krakauer H and Wren RE. An analysis of liver transplant experience from 37 transplant centers as reported to Medicare. *Transplantation* 1993; 56: 554–561.

47. Kemmer N, Kaiser T, Zacharias V, et al. Alpha-1-antitrypsin deficiency: outcomes after liver transplantation. *Transplant Proc* 2008; 40: 1492–1494.

48. Filipponi F, Soubrane O, Labrousse F, et al. Liver transplantation for end-stage liver disease associated with alpha-1-antitrypsin deficiency in children: pretransplant natural history, timing and results of transplantation. *J Hepatol* 1994; 20: 72–78.

49. Hughes MG Jr, Khan KM, Gruessner AC, et al. Long-term outcome in 42 pediatric liver transplant patients with alpha 1-antitrypsin deficiency: a single-center experience. *Clin Transplant* 2011; 25: 731–736.

50. Prchaljas AA, Kalife M, Francavilla R, et al. Liver transplantation for alpha-1-antitrypsin deficiency in children. *Transpl Int* 2000; 13: 207–210.

51. Renz JF, de Roos M, Rosenthal P, et al. Posttransplantation growth in pediatric liver recipients. *Liver Transpl* 2001; 7: 1040–1055.

52. Guillaud O, Jacquemin E, Couchonnal E, et al. Long term results of liver transplantation for alpha-1 antitrypsin deficiency. *Dig Liver Dis*. Epub ahead of print 30 October 2020. DOI: 10.1016/j.dld.2020.10.016.

53. Carey EJ, Iyer VN, Nelson DR, et al. Outcomes for recipients of liver transplantation for alpha-1-antitrypsin deficiency-related cirrhosis. *Liver Transpl* 2013; 19: 1370–1376.

54. Vennarecci G, Gunson BK, Ismail T, et al. Transplantation for end stage liver disease related to alpha 1 antitrypsin. *Transplantation* 1996; 61: 1488–1495.

55. Jain AB, Patil V, Sheikh B, et al. Effect of liver transplant on pulmonary functions in adult patients with alpha 1 antitrypsin deficiency: 7 cases. *Exp Clin Transplant* 2010; 8: 4–8.

56. Tejwani V, Wang X-F and Stoller JK. The natural history of lung function in severe deficiency of alpha-1 antitrypsin following orthotopic liver transplantation: a case report. *Chronic Obstr Pulm Dis* 2015; 2: 290–295.

57. Arnal FM, Lorenzo MJ, Suárez F, et al. Acquired PiZZ alpha-1 antitrypsin deficiency in a liver transplant recipient. *Transplantation* 2004; 77: 1918–1919.

58. Roelandt P, Dobbels P, Komuta M, et al. Heterozygous α1-antitrypsin Z allele mutation in presumed healthy donor livers used for transplantation. *Eur J Gastroenterol Hepatol* 2013; 25: 1335–1339.

59. Grannas G, Neipp M, Hoeper MM, et al. Indications for and outcomes after combined lung and liver transplantation: a single-center experience on 13 consecutive cases. *Transplantation* 2008; 85: 524–531.